Boland Brigid S, Sandborn William J, Chang John T
Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Digestive Diseases Research Development Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Digestive Diseases Research Development Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Gastroenterol Clin North Am. 2014 Sep;43(3):603-17. doi: 10.1016/j.gtc.2014.05.011. Epub 2014 Jun 24.
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.
Janus激酶（JAK）抑制剂已成为一种新型的口服小分子疗法，用于治疗溃疡性结肠炎，也可能用于治疗克罗恩病。这些分子旨在选择性地靶向特定JAK的活性，并提供一种靶向作用机制，而没有免疫原性风险。基于类风湿关节炎的临床试验数据和炎症性肠病的2期研究，托法替布和其他JAK抑制剂可能会成为治疗炎症性肠病的一种新的药物治疗形式。
